Effects of cardiozymTM supplementation on lipid profile and cardiovascular risk in patients at risk for cardiovascular disease : a retrospective chart review

Abstract

INTRODUCTION: Numerous previous studies have examined the effects of dietary supplements on cardiovascular (CV) health, but there is limited research on the effects of combined nutraceuticals on lipid profile and CV risk.

OBJECTIVES: To investigate the effects of a novel nutraceutical product (CardiozymTM) containing red yeast rice (RYR, monacolin K), hydroxytyrosol (HT), and coenzyme Q10 (CoQ10) on lipid profile and CV risk.

METHODS: In this retrospective chart review, data were collected from the medical records of 38 patients at risk for cardiovascular disease (CVD) who were started on CardiozymTM. After 6 months of supplementation, the primary outcome was improvement in lipid profile and reduction in CVD risk as measured by the Framingham Risk Score (FRS). Health parameters and CV risk scores were compared between baseline and 6-month follow-up using a paired samples t-test. Linear mixed models adjusted for patient sex, age, weight, and use of antihypertensive medication were used to test the change in each parameter from baseline to follow-up.

RESULTS: CardiozymTM had a significant beneficial effect on serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL) and non-highdensity lipoprotein cholesterol. Improvements in blood pressure levels were also observed. Significant associations were found between alcohol consumption and changes in mean LDL and triglyceride levels. After adjustment for age, sex, weight, and use of antihypertensive medications, significant reductions in mean FRS and 10-year CV risk were observed.

CONCLUSIONS: A 6-month CardiozymTM supplementation based on RYR, HT and CoQ10 not only improved lipid profile in subjects at risk of CVD but also mitigated CV risk, highlighting its effectiveness as an intervention to promote heart health.